Abstract
The aim of this study was to report our experience with activated polyacrylate dressing ‘TenderWet24®’ dressing (Paul Hartmann AG) and to establish the effectiveness of the dressing in preparing the wound bed.
Methods : A prospective case series study was conducted from March to September 2004. Patients with wounds that were assessed as being amenable to the process of autolytic debridement as a method of wound bed preparation were recruited to the study. The wounds were assessed for infection and colonisation by wound fluid cultures and wound biopsy (punch biopsy at wound margin). The arterial blood supply was assessed as needed by clinical examination and with ankle brachial indices. The amount of tissue requiring debridement was assessed and the degree of wound debridement was followed from the first application of TenderWet 24® until the wound did not require further debridement or the treatment was judged to be a failure.
Results : Ten patients were recruited for the study. There were nine males and one female patient with an overall mean age of 62 years (range 33-92 years). Diabetes mellitus was previously diagnosed in three patients. Four wound types were recorded: venous ulcer (n=4); diabetic ulcer (n=3); arterial ulcer (n=5); and wounds due to various aetiologies not included in the other four types (n=1). Biopsy of the wound was performed in six patients.
A microbiological profile was obtained in all patients. In two patients, the dressing did not achieve debridement and an alternative agent was used. We show that the use of TenderWet 24® decreased the mean surface area wounds from 26.4 cm2 to 21.4 cm2 over a mean period of 6.5 days.
Conclusion: The results of this study suggest that activated TenderWet 24® therapy is safe and effective for the debridement of all types of wounds. However, to yield statistically significant results, larger studies must be performed.
Keywords: TenderWet 24®, wound bed preparation, leg ulcer, debridement.
BP Mwipatayi, D Angel, P Dixon, S Higgins, G Gregory & K Sieunarine. Clinical experiences with activated polyacrylate dressings (Tenderwet 24®). Primary Intentions 2005; 13(2): 69-74.